Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.HemoGenix, a privately-held contract research and assay development company, has reported that the US Patent and Trademark Office has issued the first two of several patent applications for the company's Halo technology.
Subscribe to our email newsletter
The Halo Research Platform is for basic research scientists in academia and other research institutions. The Halo Stem and Progenitor Cell, Quality Control (SPC-QC) and Halo-96 PQR (Potency, Quality Release) Platforms were designed for stem cell transplantation and cord blood bank processing laboratories to address the requirement for appropriate and validated assays for umbilical cord blood stem cell products prior to transplantation into patients.
Ivan Rich, founder and CEO of HemoGenix, said: “For a small, but growing company like HemoGenix, IP is of fundamental importance to us, not only as validation for what we do, but also for future business, market share and strategic partnerships.”